BioCentury | Aug 10, 2015
Clinical News

THV01-1: Phase I/II data

...chronic HIV-1 infection on highly active anti-retroviral therapy (HAART) showed that intramuscular prime-boost vaccination with THV01-1...
...received 5x10 6, 5x10 7 and 5x10 8 transducing units doses of THV01-1 and THV01-2. THV01-1...
...in Vancouver. Theravectys S.A. , Paris, France Product: THV01-1 Business: Infectious Molecular target: NA Description: Therapeutic vaccine against HIV...
BioCentury | Aug 10, 2015
Clinical News

THV01-2: Phase I/II data

...chronic HIV-1 infection on highly active anti-retroviral therapy (HAART) showed that intramuscular prime-boost vaccination with THV01-1...
...IFN) gamma , IFN alpha and IL-2. Furthermore, 93% of patients who received the prime-boost THV01-1/THV01-2...
...received 5x10 6, 5x10 7 and 5x10 8 transducing units doses of THV01-1 and THV01-2. THV01-1...
BioCentury | Sep 1, 2014
Company News

Immune Design, Theravectys infectious, cancer news

...manufacturing process to Henogen and had no knowledge of Theravectys’ processes. Theravectys’ THV01-1 -- a therapeutic vaccine against HIV...
BioCentury | Feb 10, 2014
Clinical News

THV01-1: Completed Phase I/II enrollment

...trial evaluating 3 dose levels of intramuscular THV01-1 followed by THV01-2 given 8 weeks apart. THV01-1...
...THV01-2 are lentiviral vectors coding for the same anti-HIV antigen but that have different envelopes. THV01-1...
...Jersey serotype. Theravectys S.A. , Paris, France Product: THV01-1 Business: Infectious Molecular target: NA Description: Therapeutic vaccine against HIV...
BioCentury | Feb 10, 2014
Clinical News

THV01-2: Completed Phase I/II enrollment

...trial evaluating 3 dose levels of intramuscular THV01-1 followed by THV01-2 given 8 weeks apart. THV01-1...
...THV01-2 are lentiviral vectors coding for the same anti-HIV antigen but that have different envelopes. THV01-1...
...Jersey serotype. Theravectys S.A. , Paris, France Product: THV01-2 Business: Infectious Molecular target: NA Description: Therapeutic vaccine against HIV...
BioCentury | Oct 17, 2013
Financial News

Theravectys raises EUR 14.7 million

...investors, including Financiere IDAT and FGP Capital, also participated along with new private investors. Theravectys' THV01-1...
BioCentury | Dec 10, 2012
Clinical News

THV01-1: Phase I/II start

...dose levels of intramuscular THV01-1 followed by THV01-2 given 8 weeks apart in 36 patients. THV01-1...
...THV01-2 are lentiviral vectors coding for the same anti-HIV antigen but that have different envelopes. THV01-1...
...Jersey serotype. Theravectys S.A.S. , Paris, France Product: THV01-1 Business: Infectious Molecular target: NA Description: Therapeutic vaccine against HIV...
BioCentury | Dec 10, 2012
Clinical News

THV01-2: Phase I/II start

...dose levels of intramuscular THV01-1 followed by THV01-2 given 8 weeks apart in 36 patients. THV01-1...
...THV01-2 are lentiviral vectors coding for the same anti-HIV antigen but that have different envelopes. THV01-1...
...Jersey serotype. Theravectys S.A.S. , Paris, France Product: THV01-2 Business: Infectious Molecular target: NA Description: Therapeutic vaccine against HIV...
BioCentury | Aug 1, 2005
Product Development

Spawning success

More than a decade after DNA vaccines emerged as a novel therapeutic genre, two such products have received marketing approval just days apart, albeit for disease prevention in horses and salmon. Vical Inc. , which out-licensed...
BioCentury | Aug 25, 2003
Company News

Vical, Merck deal

The companies amended a 1997 deal under which VICL granted MRK a worldwide development and marketing license to its naked DNA delivery technology for therapeutic vaccines against HIV and hepatitis B virus (HBV) (see BioCentury,...
Items per page:
1 - 10 of 13